Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL

Am J Hematol. 2019 Apr;94(4):E117-E116. doi: 10.1002/ajh.25411. Epub 2019 Feb 4.

Affiliations

¹ Department of Medicine, Division of Medical Oncology, University of Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC.
² CHI Franciscan Health, Franciscan Inpatient Services, Federal Way, Washington, DC.
³ Department of Radiation Oncology, University of Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC.

PMID: 30663774
DOI: 10.1002/ajh.25411

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Disease-Free Survival
Female
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse / mortality*
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Patient Selection*
Survival Rate

Grants and funding